[O25-6] O25-6: Drug assay

[O25-6-3] UHPLC-MS/MS based quantification of DOACs and application to patients undergoing cardiac catheterization treated with rivaroxaban

Martin Helge Josef Wiesen¹, Cornelia Blaich², Veronika Jennissen³, Thomas Streichert⁴, Carsten Mueller⁵, Guido Michels⁶ (1.University of Cologne, 2.University of Cologne, 3.University of Cologne, 4.University of Cologne, 5.University of Cologne, 6.University of Cologne)

キーワード：DOACs, rivaroxaban, interventional procedures, LC-MS/MS, anti-FXa activity